Literature DB >> 15585390

Molecular biology of squamous cell carcinoma of the anus: a comparison of HIV-positive and HIV-negative patients.

Pascal Gervaz1, Dieter Hahnloser, Bruce G Wolff, Sarah A Anderson, Julie Cunningham, Robert W Beart, Adam Klipfel, Lawrence Burgart, Stephen N Thibodeau.   

Abstract

The molecular mechanisms involved in progression of squamous cell carcinoma of the anus (SCCA) are poorly elucidated, as well as the potential role of HIV infection. Loss of heterozygosity (LOH) is one of the mechanisms responsible for inactivation of tumor suppressor genes. We hypothesized that HIV-induced immunosuppression may contribute to an alternate molecular pathway in SCCA progression, through persistence of human papillomavirus infection within the anal canal. This study was undertaken to compare the molecular biology of SCCA in HIV-positive (HIV+) and HIV-negative (HIV-) patients. We retrieved tumor specimens from 18 HIV- and 10 HIV+ patients diagnosed with SCCA in two institutions. DNA from tumor and normal tissues was extracted and then amplified by polymerase chain reaction. LOH was investigated at 14 loci: three at 18q (DCC), two at 13q (Rb), three at 17p (p53), three at 11q, one at 2p, and two at 5q (APC). LOH was defined by a tumor DNA-to-normal tissue DNA ratio of >2. HIV+ patients were younger (36 +/- 7 years versus 53 +/- 13 years, P=0.001) and showed a trend toward tumors of larger size (3.7 +/- 1.6 cm versus 2.6 +/- 1.5 cm, P=0.09). The median CD4+ count in HIV+ patients at the time of diagnosis was 74 x 10(6)/L (range, 5-900). The overall frequency of LOH was 17.3% (41 LOH of 236 informative loci). Tumors in HIV- patients were more likely to present LOH than were tumors in HIV+ patients (24.1% versus 6.6%, P=0.0004). Differences between the two groups with regard to allelic losses were also observed at specific loci, such as 18q (41% [HIV-] versus 0% [HIV+], P=0.05), 17p (43% versus 10%, P=0.09), and 5q (33% versus 0%, P=0.12). Consistent LOH on chromosomes 17p, 18q, 5q, and 11q were observed in HIV- patients with SCCA. By contrast, allelic losses at 17p, 5q, and 18q seem to be rare in tumors of HIV+ individuals. These data suggest that immunosuppression may promote SCCA progression through an alternate pathway and that persistence of HPV infection within the anal canal may play a central role in this process.

Entities:  

Mesh:

Year:  2004        PMID: 15585390     DOI: 10.1016/j.gassur.2004.08.013

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men.

Authors:  J M Palefsky; E A Holly; M L Ralston; N Jay
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

2.  p53 gene mutation is rare in human cervical carcinomas with positive HPV sequences.

Authors:  J.-H. Lee; Y.-S. Kang; J.-W. Koh; S.-Y. Park; B.-G. Kim; E.-D. Lee; K.-H. Lee; K.-B. Park; Y.-L. Seo
Journal:  Int J Gynecol Cancer       Date:  1994-11       Impact factor: 3.437

3.  Association of human papillomavirus types 16 and 18 E6 proteins with p53.

Authors:  B A Werness; A J Levine; P M Howley
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

4.  Human papillomavirus infection in women infected with the human immunodeficiency virus.

Authors:  X W Sun; L Kuhn; T V Ellerbrock; M A Chiasson; T J Bush; T C Wright
Journal:  N Engl J Med       Date:  1997-11-06       Impact factor: 91.245

5.  Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q.

Authors:  R D Steenbergen; J M Walboomers; C J Meijer; E M van der Raaij-Helmer; J N Parker; L T Chow; T R Broker; P J Snijders
Journal:  Oncogene       Date:  1996-09-19       Impact factor: 9.867

6.  Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24.

Authors:  G M Hampton; L A Penny; R N Baergen; A Larson; C Brewer; S Liao; R M Busby-Earle; A W Williams; C M Steel; C C Bird
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

7.  Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells.

Authors:  T M Chen; G Pecoraro; V Defendi
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

8.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

Review 9.  Chapter 6: Immunosuppression and co-infection with HIV.

Authors:  Joel M Palefsky; Elizabeth A Holly
Journal:  J Natl Cancer Inst Monogr       Date:  2003

10.  A recurrent pattern of chromosomal aberrations and immunophenotypic appearance defines anal squamous cell carcinomas.

Authors:  K Heselmeyer; S du Manoir; H Blegen; B Friberg; C Svensson; E Schröck; T Veldman; K Shah; G Auer; T Ried
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  11 in total

Review 1.  The role of viral and bacterial pathogens in gastrointestinal cancer.

Authors:  Michael Selgrad; Peter Malfertheiner; Lucia Fini; Ajay Goel; C Richard Boland; Luigi Ricciardiello
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

Review 2.  Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA).

Authors:  Christian Marin-Muller; Min Li; Changyi Chen; Qizhi Yao
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

3.  Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now.

Authors:  Ashish A Deshmukh; Scott B Cantor; Elisabeth Fenwick; Elizabeth Y Chiao; Alan G Nyitray; Elizabeth A Stier; Stephen E Goldstone; Timothy Wilkin; Jagpreet Chhatwal
Journal:  Vaccine       Date:  2017-08-12       Impact factor: 3.641

4.  Anal squamous cell carcinoma in the HIV-positive patient.

Authors:  Deborah Nagle
Journal:  Clin Colon Rectal Surg       Date:  2009-05

5.  A trial of radiofrequency ablation for anal intraepithelial neoplasia.

Authors:  Robert N Goldstone; Shirin R Hasan; Steven Drury; Teresa M Darragh; Annemieke van Zante; Stephen E Goldstone
Journal:  Int J Colorectal Dis       Date:  2016-10-21       Impact factor: 2.571

Review 6.  Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexuals.

Authors:  Pascal Gervaz; Alexandra Calmy; Ymer Durmishi; Abdelkarim S Allal; Philippe Morel
Journal:  World J Gastroenterol       Date:  2011-07-07       Impact factor: 5.742

7.  Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia.

Authors:  Ashish A Deshmukh; Elizabeth Y Chiao; Prajnan Das; Scott B Cantor
Journal:  Vaccine       Date:  2014-11-01       Impact factor: 3.641

Review 8.  Diagnosis and management of anal cancer.

Authors:  Pascal Gervaz; Nicolas Buchs; Philippe Morel
Journal:  Curr Gastroenterol Rep       Date:  2008-10

9.  Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences.

Authors:  Wulfran Cacheux; Petros Tsantoulis; Adrien Briaux; Sophie Vacher; Pascale Mariani; Marion Richard-Molard; Bruno Buecher; Sophie Richon; Emmanuelle Jeannot; Julien Lazartigues; Etienne Rouleau; Odette Mariani; Elsy El Alam; Jérôme Cros; Sergio Roman-Roman; Emmanuel Mitry; Elodie Girard; Virginie Dangles-Marie; Astrid Lièvre; Ivan Bièche
Journal:  Cancer Med       Date:  2018-05-26       Impact factor: 4.452

10.  DNA methylation profiling across the spectrum of HPV-associated anal squamous neoplasia.

Authors:  Jonathan M Hernandez; Erin M Siegel; Bridget Riggs; Steven Eschrich; Abul Elahi; Xiaotao Qu; Abidemi Ajidahun; Anders Berglund; Domenico Coppola; William M Grady; Anna R Giuliano; David Shibata
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.